{
  "id": "6059f36562fc38454754d5672a05e693bbf985c5",
  "title": "Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns",
  "summary_full": "Agency updates guidance after increase in reports of condition to its yellow card schemePatients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said.About 1.6 million adults in England, Wales and Scotland used GLP-1 medication, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025 to lose weight, according to recent research. Continue reading...",
  "summary_public": "Agency updates guidance after increase in reports of condition to its yellow card schemePatients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis,â€¦",
  "url": "https://www.theguardian.com/science/2026/jan/29/small-risk-severe-acute-pancreatitis-weight-loss-jabs-mhra",
  "published_at": "2026-01-29T19:23:02+00:00",
  "source": "World news - The Guardian",
  "language": "en",
  "countries_detected": [
    "GB"
  ],
  "countries_scored": [
    "GB"
  ],
  "sentiment_error": "No batch result returned for this item",
  "llm_attempted_at": "2026-02-02T13:49:35+00:00"
}